HOPE-3 reports upper-limb function results for deramiocel in advanced Duchenne

원문 링크: WordPress 원문

The Lancet published the phase 3 HOPE-3 trial of intravenous deramiocel on August 22, 2026 , reporting 106 participants aged 10 years or older with advanced Duchenne muscular dystrophy and a 12-month group difference on the trial’s upper-limb functional endpoint . The trial does not establish long-term cardiac, walking, survival, approval, or mutation-class-wide benefit , while the randomized placebo-controlled result adds phase 3 evidence on preserving function in advanced disease .

The peer-reviewed HOPE-3 report appeared in the August 22, 2026 issue of The Lancet.

Randomized population 106 participants PubMed record

PUL2.0 LS mean difference 4.55% PubMed record

Primary time point 12 months Trial record

ENGKOR

AI-generated conceptual illustration; not study data.

HOPE-3 tested function in a later stage of Duchenne

Duchenne muscular dystrophy gradually weakens skeletal and cardiac muscle. By the time the disease is advanced, many people have already lost walking ability or have limited arm movement, so a modest change in upper-limb function can affect eating, using a phone, operating a wheelchair, and other daily tasks. HOPE-3 asked whether deramiocel could slow that functional decline. Deramiocel is an allogeneic heart-derived cellular therapy. In this study it was given by intravenous infusion in an outpatient setting every three months.

Design: phase 3, multicenter, randomized, double-blind, placebo-controlled trial.

Population: people aged 10 or older with advanced Duchenne muscular dystrophy.

Analysis: 54 assigned to deramiocel and 52 to placebo in the intention-to-treat population.

Primary endpoint: percentage change from baseline in total Performance of the Upper Limb 2.0 at one year.

The trial screened 139 people and randomized 106: 54 received deramiocel and 52 received placebo. At the primary assessment, the least-squares mean difference in total PUL2.0 percentage change favored deramiocel by 4.55 percentage points. The reported 95% confidence interval was 0.47 to 8.63, and the p value was 0.029.

Randomization distributes participants between groups by chance, while double blinding limits expectations from participants, clinicians, and assessors. A placebo control then provides a reference for the decline that occurred during the same period. These features make the functional comparison more informative than an uncontrolled before-and-after observation, but they do not extend the finding beyond the endpoint and follow-up that were measured.

PUL2.0 is a structured assessment of upper-limb tasks, scored by how a person performs defined movements. It is a functional endpoint. It is not a direct measure of heart outcomes, walking, survival, or how every daily activity changes.

AI-generated conceptual illustration; not study data.

The result concerns preservation, not restored muscle

The direction of the primary result is clinically relevant because advanced Duchenne has few opportunities to preserve remaining function. The comparison indicates that the deramiocel group lost less ground on the trial’s upper-limb scale than the placebo group over the measured period. It should not be translated into a claim that damaged muscle was rebuilt, that lost abilities returned, or that every participant experienced a noticeable improvement.

The least-squares mean difference is an adjusted comparison between groups, not the percentage of participants who improved. The confidence interval remained above zero but was broad, which leaves uncertainty about the size of the effect. The p value addresses compatibility with the null model under the analysis plan; it does not state how large or durable the benefit will be for an individual.

The study included both ambulatory and non-ambulatory people, but the publication’s primary claim is tied to the intention-to-treat population and the specified functional scale. Readers should therefore resist turning one group-level endpoint into a promise for a particular disease stage, baseline ability, or genetic subtype. The abstract describes the treatment as potentially agnostic to the underlying genetic lesion, yet this trial alone does not prove equal benefit across all mutation classes.

The practical meaning is narrower and more useful. HOPE-3 provides randomized phase 3 evidence that a quarterly intravenous cellular therapy can affect the trajectory of an upper-limb score in advanced Duchenne. Whether that difference remains stable, grows, or disappears with longer follow-up requires additional observation.

Safety looked similar, but the boundary is one year

The paper reports that deramiocel’s safety profile was similar to placebo. That sentence supports a group-level comparison within this trial. It does not mean there were no adverse events, that every risk is known, or that safety has been established across broader ages, longer exposure, and routine clinical use. Full event categories, severity, attribution, withdrawals, and repeated-dose exposure remain essential for a complete safety reading.

The main efficacy and safety statements are bounded by the randomized study population and the one-year analysis. ClinicalTrials.gov currently lists the study as active, not recruiting, with later completion information still expected. The public registry does not yet provide a posted results module, so the peer-reviewed paper is the source for the reported outcome while the registry anchors the protocol and status.

Cardiac measures were evaluated, but the abstracted primary result is the total PUL2.0 functional comparison. This article therefore does not claim a proven long-term cardiac benefit. It also does not claim preserved walking, longer survival, regulatory approval, or a replacement for existing standards of care. Those questions need endpoint-specific results, longer follow-up, regulatory review, and evidence from clinical use if approval is later granted.

The study was funded by Capricor Therapeutics, the therapy’s developer. Industry sponsorship does not invalidate a randomized trial, but it makes transparent methods, complete reporting, independent scrutiny, and replication especially important. The published confidence interval and explicit placebo comparison should remain visible whenever the result is summarized.

AI-generated conceptual illustration; not study data.

Longer follow-up must answer the questions PUL2.0 cannot

The next evidence should show whether the functional separation persists beyond the primary analysis and whether it is accompanied by changes that patients and families can recognize in daily life. Detailed subgroup reporting is also needed to understand how baseline function, age, ambulatory status, corticosteroid use, and genetic variation relate to the observed group average. These analyses should be interpreted cautiously when subgroup sizes are small.

Cardiac outcomes need their own complete presentation. A cellular therapy derived from heart tissue may invite a cardiac narrative, but biological origin is not clinical proof. Left ventricular function, myocardial scarring, hospital events, and longer-term cardiac outcomes should be evaluated on their prespecified measures rather than inferred from the upper-limb result.

Regulatory status is another separate question. A positive phase 3 endpoint can support a submission, but it is not itself marketing approval. Regulators review manufacturing consistency, benefit-risk, subgroup evidence, safety, and the full data package. Until that process is complete, deramiocel remains an investigational therapy and should not be described as an established treatment.

For families, the paper offers a meaningful but bounded finding: a placebo-controlled trial found a difference on an upper-limb functional scale after quarterly outpatient infusions. It does not yet answer how long that difference lasts or whether it changes cardiac health, walking, survival, or every genetic form of Duchenne.

Evidence boundary

This article is limited to the phase 3 HOPE-3 report and its public trial record. It does not claim cure, restored muscle, established long-term cardiac or ambulatory benefit, longer survival, regulatory approval, or mutation-class-wide efficacy.

References

PubMed: HOPE-3 phase 3 report The Lancet article DOI ClinicalTrials.gov: NCT05126758

This is science news, not medical advice. Treatment decisions for Duchenne muscular dystrophy require a qualified neuromuscular care team.